The risk of vitamin E deficiency is of primary concern in cystic fibrosis patients. However, early diagnosis and routine vitamin E supplementation can lead to its normal or even high levels.
There is growing concern regarding the risk of transfusion- transmitted (TT) hepatitis E. Since the first described case in 2006, several TT hepatitis E have been reported to the French hemovigilance network.
Eisai has disclosed the first clinical data (Phase 1) for its new early stage candidate for Alzheimer's disease, the beta-site...
Nexstim has completed its supplementary Phase III clinical trial, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR...
Biological E. Limited (BE), one of the world’s largest vaccine manufacturers, has announced that its Corbevax, India’s first indigenously developed protein sub-unit vaccine against COVID-19, received the approval from the Drugs Controller General of India (DGCI).
Metaperex 400 IU soft capsules is indicated in the following conditions for adults: • Vitamin E deficiency in patients diagnosed with ataxia with vitamin E deficiency (AVED).
Baxter International Inc. a global leader in clinical nutrition, announced the FDA approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections.
Sporadic hepatitis E is an emerging indigenous disease in Europe induced by genotype 3 of the virus. While the disease takes an acute self-limited course in immunocompetent individuals, under immunocompromised...
Acucela has announced top-line results from the Phase IIb/III clinical trial (S.E.A.T.T.L.E. study) of the investigational visual cycle modulator emixustat...
Eisai announced that a new drug application has been submitted to the FDA for E 2006 (lemborexant), an investigational agent...